Literature DB >> 15271907

Characterization of an I-E-restricted, gp63-specific, CD4-T-cell clone from Leishmania major-resistant C3H mice that secretes type 2 cytokines and exacerbates infection with L. major.

Cynthia M Theodos1, Robin V Morris, Jeanette V Bishop, Jeremy D Jones, W Robert McMaster, Richard G Titus.   

Abstract

A T-cell clone (designated KLmB-3) was derived from resistant C3H mice 2 weeks after infection with Leishmania major. KLmB-3 was a CD4-T-cell clone that utilized the V beta 8.1 T-cell receptor. When adoptively transferred to naive C3H mice, KLmB-3 unexpectedly exacerbated infection with L. major (it increased the cutaneous lesion size and the parasite burden within the lesion). The ability of KLmB-3 to exacerbate disease correlated with its ability to produce the type 2-associated cytokines interleukin-4 (IL-4), IL-5, IL-10, and transforming growth factor beta. Interestingly, KLmB-3 was specific for an epitope in the amino-terminal end of the L. major surface gp63 zinc metalloproteinase (leishmanolysin) that has been shown to be capable of inducing a protective immune response. Moreover, KLmB-3 was activated when this epitope was presented in the context of H-2 I-E rather than H-2 I-A.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271907      PMCID: PMC470630          DOI: 10.1128/IAI.72.8.4486-4493.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

Review 1.  Cytokines in parasitic diseases: the example of cutaneous leishmaniasis.

Authors:  P Launois; F Tacchini-Cottier; C Parra-Lopez; J A Louis
Journal:  Int Rev Immunol       Date:  1998       Impact factor: 5.311

2.  IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice.

Authors:  P Launois; I Maillard; S Pingel; K G Swihart; I Xénarios; H Acha-Orbea; H Diggelmann; R M Locksley; H R MacDonald; J A Louis
Journal:  Immunity       Date:  1997-05       Impact factor: 31.745

Review 3.  Type 1 and type 2 responses to Leishmania major.

Authors:  Kathleen A Rogers; Gregory K DeKrey; M Lamine Mbow; R Dean Gillespie; Claudia I Brodskyn; Richard G Titus
Journal:  FEMS Microbiol Lett       Date:  2002-03-19       Impact factor: 2.742

4.  Expression cloning of a protective Leishmania antigen.

Authors:  E Mougneau; F Altare; A E Wakil; S Zheng; T Coppola; Z E Wang; R Waldmann; R M Locksley; N Glaichenhaus
Journal:  Science       Date:  1995-04-28       Impact factor: 47.728

Review 5.  The in vitro generation and functional analysis of murine T cell populations and clones specific for a protozoan parasite, Leishmania tropica.

Authors:  J A Louis; R H Zubler; S G Coutinho; G Lima; R Behin; J Mauel; H D Engers
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

6.  Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection.

Authors:  D Rivier; P Bovay; R Shah; S Didisheim; J Mauël
Journal:  Parasite Immunol       Date:  1999-09       Impact factor: 2.280

7.  Leishmania major: production of recombinant gp63, its antigenicity and immunogenicity in mice.

Authors:  E Handman; L L Button; R W McMaster
Journal:  Exp Parasitol       Date:  1990-05       Impact factor: 2.011

8.  Correcting an immune-response deficiency by creating E alpha gene transgenic mice.

Authors:  M Le Meur; P Gerlinger; C Benoist; D Mathis
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

9.  Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice.

Authors:  F P Heinzel; R M Rerko; F Ahmed; E Pearlman
Journal:  J Immunol       Date:  1995-07-15       Impact factor: 5.422

10.  Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines.

Authors:  B J Holaday; M D Sadick; Z E Wang; S L Reiner; F P Heinzel; T G Parslow; R M Locksley
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.